Company profile
Appili Therapeutics Inc
OTC: APLIF · Healthcare · Biotechnology
Canadian filerHQ Halifax, NSReports USD
#1012 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
28DFH 21DQ —GM 50SS 26
v0.1 · 45/100 weight · provisional
↑ revenue growth (YoY), disclosure history · ↓ balance-sheet leverage, Altman-Z
Methodology →Revenue TTM
$273.7k
Rev growth YoY (TTM)
+279.4%
Net income (FY)
-$3.1M
Employees
7
as of 2026-08-25
Market cap
$1.2M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$177.1k244.8k CAD2026
Net income-$3.1M-4.3M CAD2026
Operating income-$4.7M-6.6M CAD2026
Total assets$1.4M2.0M CAD2026
Liabilities$13.9M19.4M CAD2026
Equity-$12.5M-17.4M CAD2026
Revenue trend
FY2019 – FY2026 · USD
FY19
FY20
FY21
FY22
FY23
FY24
FY25
FY26
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Appili Therapeutics Inc’s revenue?
Appili Therapeutics Inc booked $177.1k in FY2026 revenue, growing 145% year over year — faster than most Healthcare companies we track, at a -1736.7% net margin.
Peers · Healthcare
Abpro Holdings, Inc.14DPharmaRoth Labs, Inc.——Panacos Pharmaceuticals, Inc.——MedMira Inc.31DEden Empire Inc.——Lisata Therapeutics, Inc.39DKey facts
CEODon Cilla
SectorHealthcare
IndustryBiotechnology
HeadquartersHalifax, NS
ExchangeOTC: APLIF
Employees7
IPO date2021-01-08
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.